iSpecimen Inc. — Fiscal 2023 Form 10-K Summary
Business context and reporting period
The filing covers the fiscal year ended December 31, 2023; it is an annual report rather than a standalone fourth-quarter filing. iSpecimen operates a single business segment: a technology-enabled marketplace connecting life-science researchers with healthcare providers and other sources of human biospecimens and associated data. Revenue is generated primarily from procuring and distributing specimens; customers and suppliers are not currently charged separate marketplace-access fees.
- Marketplace network included approximately 234 supply organizations in 19 countries and approximately 709 customers as of December 31, 2023.
- The platform had more than 7,428 external registered users and had delivered more than 210,000 specimens supporting nearly 3,000 projects since inception.
- The Company had 53 employees at year-end.
Financial performance and liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $9.93 million | $10.40 million | Down 5% |
| Cost of revenue | $4.82 million | $4.76 million | Up 1% |
| Gross profit | Approximately $5.11 million | Approximately $5.65 million | Down approximately 10% |
| Gross margin | Approximately 51.4% | Approximately 54.3% | Down approximately 2.9 percentage points |
| Operating loss | $(11.17) million | $(10.19) million | Loss widened 10% |
| Net loss | $(11.10) million | $(10.25) million | Loss widened 8% |
| Net loss per share | $(1.23) | $(1.16) | More dilutive loss per share |
| Operating cash flow | $(5.81) million | $(5.82) million | Essentially unchanged |
| Cash and cash equivalents | $2.34 million | $15.31 million | Down 85% |
| Available-for-sale securities | $2.66 million | — | New balance-sheet item |
| Working capital | $2.19 million | $15.39 million | Down 86% |
- Cash, cash equivalents and available-for-sale securities totaled approximately $5.01 million at year-end, compared with $15.31 million at December 31, 2022.
- Net cash used in investing activities was $7.23 million, including $3.77 million capitalized for internally developed software, $958,000 capitalized for sequenced data and $2.48 million net purchases of Treasury bills.
- Net cash provided by financing activities was $71,000, primarily from stock-option exercises. The $3.5 million term-loan repayment occurred in 2022; no term loan or bridge notes remained outstanding at December 31, 2023.
- Current liabilities were $6.05 million, including $3.93 million of accounts payable, $1.54 million of accrued expenses and $416,000 of deferred revenue.
Material changes versus the prior comparable period
- Revenue declined 5%, primarily because specimen volume fell 11% to 24,565 specimens. The decline was partly offset by a 7% increase in average selling price to approximately $404 per specimen.
- Average cost per specimen increased 13% to approximately $196, contributing to lower gross margin.
- Technology expense increased 34% to $3.57 million, largely due to higher amortization of internally developed software. The Company capitalized $3.77 million of internally developed software costs, versus $2.98 million in 2022.
- Sales and marketing expense increased 15% to $3.96 million, while supply development expense increased 29% to $1.03 million.
- Fulfillment expense decreased 10% to $1.79 million and general and administrative expense decreased 14% to $5.94 million, partly reflecting lower severance and compensation costs.
- One customer represented approximately 25% of 2023 revenue, compared with two customers representing approximately 14% and 12% in 2022. Revenue is transactional and non-recurring, making period-to-period results difficult to forecast.
- The Company increased its allowance for doubtful accounts by $289,898 because certain customers lacked liquidity or filed for bankruptcy.
Guidance, outlook, risks and unusual items
- Going concern: The auditor included an emphasis-of-matter paragraph, and management disclosed substantial doubt about the Company’s ability to continue as a going concern for one year after the filing date. Management plans to increase revenue, reduce expenses and capital spending, and pursue additional financing, but stated that these plans are not considered probable and do not alleviate the doubt.
- Cost reductions: Workforce reductions, primarily in September 2023, reduced estimated monthly compensation costs by 29% and reduced other monthly expenditures by more than 50% for the remainder of the year.
- Revenue initiatives: Management launched a sequenced FFPE cancer-tissue initiative in late 2023 and expects related purchase orders primarily to be fulfilled in 2024. It is also developing a potential subscription or licensing model for sequenced research data.
- Financing: On March 5, 2024, the Company entered into an ATM agreement permitting sales of up to $1.5 million of common stock. Any issuance could dilute existing stockholders.
- Warrant repurchase: On February 13, 2024, the Company repurchased and terminated PIPE warrants covering 1.3125 million shares.
- Sales-tax exposure: The Company accrued approximately $707,000 of estimated sales-tax liability and approximately $215,000 of related interest and penalties at year-end. It recovered approximately $359,000 from certain customers and recognized an approximately $564,000 loss during 2023 related to the liability. Voluntary disclosure filings with taxing jurisdictions were being initiated.
- Internal controls: Management concluded that disclosure controls and internal control over financial reporting were ineffective because of a material weakness involving sales-tax exemption documentation, calculation, collection, reporting and remittance. Remediation is ongoing and may require additional costs.
- Nasdaq listing risk: Nasdaq notified the Company in October 2023 that its common stock did not meet the $1.00 minimum bid-price requirement. The initial compliance period extended to April 8, 2024, with a possible additional period and a potential reverse stock split contemplated by management.
- Operating risks: Key risks include limited liquidity, dependence on additional capital, customer and supplier concentration, non-recurring project-based demand, cybersecurity and data-privacy exposure, regulatory compliance, specimen availability and quality, international logistics, competition, and the possibility of continued losses.
Most important facts for investors to verify
- Current cash burn, liquidity runway and whether the ATM facility or other financing has been used after the filing date.
- Whether management has improved revenue, gross margin and operating cash flow through 2024, including fulfillment of the sequenced FFPE purchase orders.
- Status and final amount of sales-tax liabilities, voluntary disclosure agreements, customer recoveries and remediation of the material weakness.
- Compliance with Nasdaq’s minimum bid-price requirement and any reverse stock split or delisting proceedings.
- Customer concentration, accounts-receivable collectability and exposure to additional customer bankruptcies.
- Actual recurring revenue, if any, from sequenced-data subscriptions or other marketplace-adjacent offerings.
- Ability to fund technology investment and operations without materially diluting shareholders or incurring unfavorable debt.